J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

Just hours af­ter J&J’s on­col­o­gy team bragged about scor­ing a break­through ther­a­py des­ig­na­tion for their BC­MA CAR-T drug, they pulled the wraps off of the mul­ti­ple myelo­ma da­ta for JNJ-4528 that im­pressed the FDA. And it’s easy to see why they may well be on a short path to a land­mark ap­proval — which may well be mak­ing the ri­val team at blue­bird/Bris­tol-My­ers more than a lit­tle ner­vous.

Fol­low­ing up on some at­ten­tion-grab­bing da­ta ini­tial­ly pre­sent­ed by their Chi­nese de­vel­op­ment part­ners at Leg­end 2 years ago dur­ing AS­CO, in­ves­ti­ga­tors say they tracked some jaw-drop­ping re­sults that con­firmed the ear­ly promise of a ther­a­py that’s shak­ing up a crowd­ed field led by blue­bird bio.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER